Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

As the guests of honor, they walked down a red carpet, free of kids for the night, to enjoy time with others in the community ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the ...

Tyler ISD Police Department arrested three employees on Friday. Dr. Marty Crawford said it did involve a student with ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.